Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. From Wikipedia
Presented at ASCO, the phase II study indicates that adding cetuximab to avelumab may offer a new treatment path for patients who progress after initial PD-1 therapy.
